CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.
Natera’s lung transplant biomarker study validates noninvasive dd-cfDNA surveillance model
Can a blood test replace lung biopsies? Natera’s Prospera test may reshape transplant care. Learn what the latest study means for diagnostics in organ health.